Our Partners

Integrating partnerships and collaborations into our core business strategy

Connect with us

To explore partnership opportunities, please contact bd@zymeworks.com

Working with great partners and collaborators forms a core part of our corporate strategy, and allow us to expand and accelerate our efforts to bring novel multifunctional therapeutics to the broadest group of patients in the most efficient manner possible.

Our partnerships and collaborations focus on:

Development and commercialization of current and future product candidates
Clinical and research collaborations that broaden the potential of our internal ADC and MSAT platforms
Collaborations with early-stage companies to access technologies and programs that are complementary to our internal ADC and MSAT capabilities

Our Commercial Partners for Zanidatamab

Jazz Pharmaceuticals

Collaboration with Jazz Pharmaceuticals for the research, development, and commercialization of zanidatamab in in the United States, Europe, Japan and all other territories except for those Asia/Pacific territories that Zymeworks previously licensed to BeiGene.

BeiGene

Collaboration with BeiGene for the research, development, and commercialization of zanidatamab and zanidatamab zovodotin (ZW49) in Asia (excluding Japan), Australia, and New Zealand and also the research, development, and commercialization of up to three bispecific antibody therapeutics globally enabled using Zymeworks’ proprietary Azymetric™ and EFECT™ platforms.

Our Clinical Collaborators

Pfizer

Entered into a clinical collaboration to evaluate the combination of Pfizer’s Ibrance® (palbociclib), an oral CDK4/6 inhibitor, and the hormone therapy fulvestrant with Zymeworks’ zanidatamab in patients with previously-treated locally advanced and/or metastatic HER2-positive, HR-positive breast cancer. Zymeworks is the sponsor of the study and Pfizer is providing palbociclib.

ALX Oncology

Entered into a clinical collaboration to evaluate the combination of Zymeworks’ zanidatamab, a HER2-targeted bispecific antibody, and ALX148, a next-generation CD47 blocker, for the treatment of patients with advanced HER2-expressing breast cancer and other solid tumors. Zymeworks is the sponsor of the study.